NEPHROPLUS share price, P/E, ROE & financials

On 6 Nov 2026, Nephrocare Health Services was priced at ₹601.75, or 47.5× trailing earnings, against an industry P/E of 47.7×, and the shares are 23% below their 52-week high. It earns ROCE of 13% and ROE of 9.0%, and sales grew 34% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹6,051 Cr, ranked 15th of 40 Medical Care Facilities companies by market cap; the shares rose 28% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹606.40
Day high: ₹609.25
Day low: ₹590.00
Prev. close: ₹603.10
Volume: 1.1 L

Health check

2 good · 3 fair · 1 to check

ReturnsAhead
+28.0% over a year, better than 7 of 7 peers.
Price tagIn line
P/E 47.5 vs industry 47.7.
GrowthStrong
Sales +33.9% a year over 3 years.
ProfitabilityAverage
ROCE 13.3% vs peer median 11.9%.
Balance sheetFair
Debt 0.07× equity, interest covered 2.7×, Piotroski 5 of 9.
Red flags1 to check
Promoter stake down from 63.9% to 58.3%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Care Facilities

39 listed peers. Screen the industry

Small cap

₹6,051 Cr, #15 of 40 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹1,053 Cr · profit ₹85 Cr

Market cap: ₹6,051 Cr; Small cap
P/E: 47.5; Industry 47.7
Price to book: 5.41; Peers 8.03
Dividend yield: 0.00%
ROE: 9.0%; Peers 12.8%
ROCE: 13.3%; Peers 11.9%
Debt to equity: 0.07; Debt ₹80 Cr
EPS (TTM): ₹12.68; Face value ₹2
OPM (TTM): 23.1%; Net margin 8.1%
Sales growth: +23.7%; Latest quarter vs a year ago
Profit growth: +34.9%; Latest quarter vs a year ago
Price to sales: 5.75; EV/EBITDA 25.9

Strengths

Practically debt-free.
Quarterly profit up 34.9% on a year ago.
Quarterly sales up 23.7% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

Promoter stake down from 63.9% to 58.3%.

Derived automatically from reported figures. Not a recommendation.

About Nephrocare Health Services

Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India.

Headquarters: Hyderabad
Employees: 2,294
Sector: Healthcare
ISIN: INE428V01029
Website: nephroplus.com

Price range

52 weeks

₹446.00₹781.50

Today

₹590.00₹609.25

Avg volume (3M): 3.5 L
1-year return: plus 28.0%
From 52-week high: minus 23.0%

Analyst consensus

5 analysts

No consensusMean target ₹836.00 38.9%

Target range, with today’s price

Low ₹755.00High ₹1,000.00

Today’s price ₹601.75 is below the lowest analyst target.

Consensus from Yahoo Finance. Not a recommendation.

Peers · Medical Care Facilities

Compare with peers Screen the whole industry

Company
APOLLOHOSPApollo Hospitals Enterprise	8,446.00	plus 0.90%	1,21,441	54.0	11.45	19.2%	22.5%	15.1%	14.8%	33.3%	0.24%	plus 7.2%
MAXHEALTHMax Healthcare Institute	934.00	plus 0.21%	90,909	66.1	8.03	12.6%	12.8%	26.8%	22.4%	9.3%	0.21%	minus 18.1%
MANIPALHOSManipal Health Enterprises	646.70	minus 1.61%	85,065	133.6	9.05	9.8%	9.2%	17.8%	–	–	0.00%	minus 1.5%
ASTERDMAster DM Quality Care	713.15	minus 0.89%	62,092	115.6	8.03	9.4%	9.7%	19.2%	15.7%	−3.0%	0.42%	plus 4.5%
FORTISFortis Healthcare	766.90	minus 6.45%	57,898	55.3	5.52	11.9%	11.1%	22.4%	13.3%	20.9%	0.12%	minus 19.6%
NHNarayana Hrudayalaya	1,903.00	minus 0.65%	38,650	44.7	7.73	11.4%	19.1%	18.5%	20.5%	9.9%	0.23%	plus 4.7%
MEDANTAGlobal Health	1,387.60	minus 0.15%	37,264	60.4	8.63	15.0%	15.2%	20.9%	17.2%	19.5%	0.04%	plus 11.2%
NEPHROPLUSNephrocare Health Services	601.75	minus 0.22%	6,051	47.5	5.41	13.3%	9.0%	14.0%	33.9%	–	0.00%	plus 28.0%
Median of 7 peers	–	−0.65%	62,092	60.4	8.03	11.9%	12.8%	19.2%	16.5%	14.7%	0.21%	4.5%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
228	244	260	266	282
180	180	199	212	218
47.6	64.2	60.9	53.8	63.9
20.9%	26.3%	23.4%	20.2%	22.7%
6.6	1.6	3.3	8.5	3.9
6.1	44.2	6	3.2	2.2
19.5	22.3	21.9	25.8	24.5
28.5	−0.6	36.4	33.2	41
16.9%	−1413.7%	11.3%	8.6%	22.1%
23.7	−9.5	32.2	30.4	32
2.36	–	3.35	2.96	3.11

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +33.9%
ROE: 9.0%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
415	540	748	994
–	+30.2%	+38.7%	+32.9%
364	431	577	766
50.5	108	171	228
12.2%	20.1%	22.9%	23.0%
4.3	4.6	10.4	10
14.6	19	18.9	58
46.9	54.9	72.5	89.5
−1.9	−5.9	−3.1	6.5
−8.6	33.2	87.4	97.5
−37.2%	−5.9%	23.3%	21.2%
−11.8	35.1	67.1	76.8
–	–	+91.0%	+14.5%
-1.17	3.50	6.69	8.10

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1.7	1.7	1.8	20.1
387	412	582	1,096
214	268	258	79.7
63.9	124	155	275
666	806	996	1,471
253	306	334	415
33	1.9	10.4	18.5
22.4	–	0.4	35.2
65.2	79.6	189	457
293	419	462	546
666	806	996	1,471

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
11.3	72.3	135	233
−78.2	−50.7	−125	−410
60	26.7	54.4	157
−7	48.4	64.6	−20.7
−73.7	−80	−101	−119
−62.5	−7.7	34.6	113

Shareholding pattern

Source: NSE filings

58.3%

promoters

Promoters58.31%
Public41.69%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	58.31%	41.69%	minus 5.54
30 Jun 2026	63.85%	36.15%	0.00
31 Mar 2026	63.85%	36.15%	0.00
31 Dec 2025	63.85%	36.15%	0.00
16 Dec 2025	63.85%	36.15%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you